Cases 11 - 20 of 146
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al
as 1:2022cv01226
Plaintiff:
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Defendant:
Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al
as 1:2022cv01125
Plaintiff:
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Defendant:
Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Bayer Pharma AG, et al v. Mylan Pharmaceuticals Inc. et al
as 1:2022cv01228
Plaintiff:
Bayer Pharma AG and Bayer AG
Counter Defendant:
Janssen Pharmaceuticals Inc.
Defendant:
Mylan Pharmaceuticals Inc.
Counter Claimant:
Mylan Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novo Nordisk, Inc. et al v. Mylan Pharmaceuticals, Inc.
as 1:2022cv01040
Counter Defendant:
Novo Nordisk Inc.
Plaintiff:
Novo Nordisk A/S
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Somaxon Pharmaceuticals Inc
as 1:2022mc00275
Respondent:
Somaxon Pharmaceuticals Inc., Currax Pharmaceuticals LLC, Currax Holdings LLC and others
Petitioner:
Mylan Inc. and Mylan Pharmaceuticals Inc.
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al
as 1:2022cv00464
Plaintiff:
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Defendant:
Mylan Laboratories Limited, Viatris Inc. and Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. et al
as 1:2022cv00451
Plaintiff:
Novartis Pharmaceuticals Corporation
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al
as 1:2018cv01043
Defendant:
Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc. and others
Counter Claimant:
Biocon Limited, HEC Pharm Group, HEC Pharm Co., Ltd. and others
Counter Defendant:
Novartis Pharmaceuticals Corporation
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Entresto (Sacubitril/Valsartan) Patent Litigation
as 1:2020md02930
Counter Claimant:
Biocon Pharma Limited, Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd. and others
Not Classified By Court:
Hetero USA Inc.,, Torrent Pharma Inc., Zydus Pharmaceuticals (USA) Inc. and others
In Re:
Entresto (Sacubitril/Valsartan) Patent Litigation
Counter Defendant:
Novartis Pharmaceuticals Corporation
Defendant:
Noratech Labs, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
as 1:2019md02902
Counter Defendant:
Merck Sharp & Dohme Corp.
Not Classified By Court:
Teva Pharmaceuticals USA, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and others
Counter Claimant:
Macleods Pharmaceuticals Limited
In Re:
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
Defendant:
Accord Healthcare, Inc., Teva Pharmaceutical Industries Ltd., Inventia Healthcare Ltd. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
